Suppr超能文献

基于血清学调查的2021年年中加蓬(中非)SARS-CoV-2感染扩展趋势及新冠疫情负担

Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021, based on a serological survey.

作者信息

Iroungou Berthe A, Moussavou Pamela Boundzanga, Elguero Eric, Makran Jamal, Bivigou-Mboumba Berthold, Wora Elise, Nzenze Jean R, Niama Fabien Roche, Aghokeng Avelin F

机构信息

Unité Mixte de Recherche, Centre International de Recherches Médicales de Franceville et le Service de Santé Militaire, Libreville, Gabon.

MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.

出版信息

IJID Reg. 2022 Dec;5:13-17. doi: 10.1016/j.ijregi.2022.08.006. Epub 2022 Aug 27.

Abstract

OBJECTIVE

To estimate the seroprevalence of anti-SARS-CoV-2 antibodies in the general population in Gabon, Central Africa.

METHODS

From May to July 2021, a cross-sectional study involving participants recruited in the general population in three districts in Gabon was conducted. Eligible participants who provided written informed consent were tested for anti-SARS-CoV-2 antibodies using a simple rapid diagnostic assay.

RESULTS

Overall, 1609 participants were recruited, 1361 (84.6%) from urban sites and 248 (15.4%) from a rural area. The estimated overall seroprevalence was 13.1% (95% CI 11.4-14.8%). The risk of seropositivity increased with age, and the prevalence in the different age groups ranged from 12.9% (8.0-19.4%) in those aged 15-24 years to 23.3% (14.2-34.6%) in those ≥ 65 years old. A higher prevalence was found in the rural population (17.3%; 12.8-22.6%) compared with urban regions (12.3%; 10.6-14.1%). Being a woman was also associated with higher risk of infection ( < 0.001).

CONCLUSIONS

This seroprevalence survey revealed a moderate seroprevalence in Gabon, illustrating a relatively low rate of circulation of the virus in the country and correlating with low numbers of confirmed cases and deaths reported to date.

摘要

目的

评估中非加蓬普通人群中抗SARS-CoV-2抗体的血清流行率。

方法

2021年5月至7月,在加蓬三个地区开展了一项横断面研究,研究对象为从普通人群中招募的参与者。对提供书面知情同意书的符合条件的参与者,使用简单快速诊断检测法检测抗SARS-CoV-2抗体。

结果

总体上,共招募了1609名参与者,其中1361名(84.6%)来自城市地区,248名(15.4%)来自农村地区。估计总体血清流行率为13.1%(95%置信区间11.4-14.8%)。血清阳性风险随年龄增加而升高,不同年龄组的流行率范围为15-24岁人群中的12.9%(8.0-19.4%)至65岁及以上人群中的23.3%(14.2-34.6%)。农村人口的流行率(17.3%;12.8-22.6%)高于城市地区(12.3%;10.6-14.1%)。女性感染风险也更高(<0.001)。

结论

这项血清流行率调查显示加蓬的血清流行率处于中等水平,说明该国病毒传播率相对较低,且与迄今报告的确诊病例数和死亡人数较少相关。

相似文献

2
Prevalence of SARS-CoV-2 antibodies in the Republic of Congo in mid-2021.
IJID Reg. 2022 Dec;5:121-123. doi: 10.1016/j.ijregi.2022.09.012. Epub 2022 Oct 6.
4
High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
mSphere. 2021 Dec 22;6(6):e0068521. doi: 10.1128/mSphere.00685-21. Epub 2021 Nov 24.
5
Seroprevalence of Toxocara spp. in a rural population in Central African Gabon.
Parasitol Int. 2016 Dec;65(6 Pt A):632-634. doi: 10.1016/j.parint.2016.09.001. Epub 2016 Sep 2.
6
Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
Braz J Infect Dis. 2021 Jul-Aug;25(4):101604. doi: 10.1016/j.bjid.2021.101604. Epub 2021 Aug 10.
8
Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.
Rev Med Virol. 2022 Mar;32(2):e2271. doi: 10.1002/rmv.2271. Epub 2021 Jul 6.
9
Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India.
J Epidemiol Glob Health. 2021 Dec;11(4):364-376. doi: 10.1007/s44197-021-00012-6. Epub 2021 Oct 26.
10
COVID-19 seroprevalence in Pakistan: a cross-sectional study.
BMJ Open. 2022 Apr 6;12(4):e055381. doi: 10.1136/bmjopen-2021-055381.

引用本文的文献

1
Time to SARS-CoV-2 clearance in African, Caucasian, and Asian ethnic groups.
Influenza Other Respir Viruses. 2024 Jun;18(6):e13238. doi: 10.1111/irv.13238.

本文引用的文献

1
Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya.
PLoS One. 2021 Dec 17;16(12):e0260989. doi: 10.1371/journal.pone.0260989. eCollection 2021.
3
High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya.
Int J Infect Dis. 2021 Nov;112:25-34. doi: 10.1016/j.ijid.2021.08.062. Epub 2021 Sep 2.
4
Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response.
J Immunol Methods. 2021 Sep;496:113096. doi: 10.1016/j.jim.2021.113096. Epub 2021 Jul 6.
5
Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.
Rev Med Virol. 2022 Mar;32(2):e2271. doi: 10.1002/rmv.2271. Epub 2021 Jul 6.
6
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.
Nat Commun. 2021 Jun 25;12(1):3966. doi: 10.1038/s41467-021-24062-3.
8
Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey.
Lancet Glob Health. 2021 Jun;9(6):e773-e781. doi: 10.1016/S2214-109X(21)00053-X. Epub 2021 Mar 9.
9
Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests.
J Virol Methods. 2021 Apr;290:114067. doi: 10.1016/j.jviromet.2021.114067. Epub 2021 Jan 18.
10
Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
JAMA Netw Open. 2021 Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验